Video

Dr. Dimou on Managing Disease Progression in NSCLC

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

Anastasios (Tassos) Dimou, MD, a medical oncologist at Mayo Clinic, shares advice from managing patients with non–small cell lung cancer (NSCLC) who experience disease progression following therapy.

For patients who progress on therapy, one approach is to rebiopsy, if possible, says Dimou; a tissue biopsy, a liquid biopsy, or both can be used, says Dimou. Several factors should be considered when choosing a patient’s next line of therapy.

First, one must identify whether they are experiencing oligoprogression; in this case, a local approach like radiation and staying the course with the same TKI might be considered.

Another question to contemplate is whether comprehensive retesting with a rebiopsy would identify mechanisms of resistance, and whether that mechanism of resistance is target oncogene dependent or independent, adds Dimou.

Additionally, the question of whether the patients is dealing with progression in the brain or with disease in the brain should also be taken into consideration; in this case, the use of a CNS-penetrant TKI might serve as an effective approach, concludes Dimou.

Related Videos
Daniel E. Haggstrom, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.